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Abstract
Background: To elucidate the incidence of acute kidney injury (AKI) after out-of-hospital cardiac arrest (OHCA) and to
examine the impact of target temperature management (TTM) and early coronary angiography on renal function.
Methods: Post hoc analysis of the TTM trial, a multinational randomised controlled trial comparing target temperature of
33 °C versus 36 °C in patients with return of spontaneous circulation after OHCA. The impact of TTM and early angiography
(within 6 h of OHCA) versus late or no angiography on the development of AKI during the 7-day period after OHCA was
analysed. AKI was defined according to modified KDIGO criteria in patients surviving beyond day 2 after OHCA.
Results: Following exclusions, 853 of 939 patients enrolled in the main trial were analysed. Unadjusted analysis showed that
significantly more patients in the 33 °C group had AKI compared to the 36 °C group [211/431 (49%) versus 170/422 (40%)
p = 0.01], with a worse severity (p = 0.018). After multivariable adjustment, the difference was not significant (odds ratio 0.75,
95% confidence interval 0.54–1.06, p = 0.10].
Five hundred seventeen patients underwent early coronary angiography. Although the unadjusted analysis showed less AKI
and less severe AKI in patients who underwent early angiography compared to patients with late or no angiography, in
adjusted analyses, early angiography was not an independent risk factor for AKI (odds ratio 0.73, 95% confidence interval
0.50–1.05, p = 0.09).
Conclusions: In OHCA survivors, TTM at 33 °C compared to management at 36 °C did not show different rates of AKI and
early angiography was not associated with an increased risk of AKI.
Trial registration: NCT01020916. Registered on www.ClinicalTrials.gov 26 November 2009 (main trial).
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Background
Cardiac arrest (CA) with a return of spontaneous circu-
lation (ROSC) represents a multisystem insult. Although
neurological injury accounts for the majority of deaths,
refractory cardiovascular failure is common. The post
cardiac arrest syndrome is characterised by multi-organ
dysfunction as a result of an acute inflammatory re-
sponse and persistent haemodynamic instability.
Ischaemia-reperfusion injury and on-going shock may
aggravate renal injury [1–3]. Acute kidney injury (AKI)
is common in these circumstances, affecting 12–81% of
patients depending on definition and patient selection
[1, 2, 4, 5]. It is possible that routine therapeutic inter-
ventions and diagnostic procedures, such as target
temperature management (TTM) and scans with con-
trast, impact the development of organ dysfunction, in-
cluding the development of AKI.
There are limited data on the renal effect of induced
hypothermia and TTM after CA with ROSC. In the
hypothermia after cardiac arrest study [6], patients rando-
mised to treatment at 33 °C had a lower calculated glom-
erular filtration rate compared to controls [7]. In other
clinical circumstances, hypothermia and rewarming had
mixed effects [8, 9]. Prolonged hypothermia after coronary
artery bypass surgery did not confer renoprotection, and
relatively rapid rewarming to normothermia during car-
diopulmonary bypass was associated with more renal dys-
function than less aggressive rewarming [10].
The acute coronary syndrome is a common cause of
CA. Current recommendations for ST-elevation myocar-
dial infarction (STEMI) after CA with ROSC include
emergent coronary angiography, and if necessary, percu-
taneous coronary intervention (PCI) within 120min [11].
However, in comatose CA patients after non-STEMI, the
decision for angiography and the optimal timing remains
controversial [11, 12]. Trials are addressing the
risk-benefit ratio of emergent coronary angiography in this
patient group [13, 14]. Whether early angiography impacts
the risk of AKI after CA is unknown.
The aims of this post hoc analysis were to describe the
incidence and outcome of AKI in survivors of
out-of-hospital CA (OHCA) of presumed cardiac origin
and to investigate the impact of TTM and early coronary
angiography.
Methods
We performed a post hoc analysis of the target
temperature management trial, a parallel group rando-
mised clinical trial in 36 intensive care units (ICUs) in
Europe and Australia between 2010 and 2013 which
compared the effect of treatment at 33 °C or 36 °C fol-
lowing ROSC on all-cause mortality (trial registration
number NCT01020916, registered on www.Clinical-
Trials.gov 26 November 2009). The rationale and main
results have already been reported [15]. Ethics commit-
tees in all participating countries approved the protocol.
Waived, delayed and/or consent from legal surrogates
and delayed written informed consent from patients
regaining mental capacity were obtained according to
decisions by ethical boards in respective countries.
Patient population
Comatose adult patients with ROSC after OHCA of the
presumed cardiac cause were eligible for inclusion. Pa-
tients were excluded if the time between ROSC and
screening exceeded 4 h, CA was unwitnessed with asys-
tole as first recorded rhythm, intracranial bleeding or is-
chaemic stroke was suspected or initial temperature on
admission was less than 30 °C. Sustained ROSC was de-
fined as no requirement for chest compressions for 20
consecutive minutes and persisting signs of circulation,
including systolic blood pressure (BP) > 80 mmHg with
or without vasoactive drugs. The time of ROSC was de-
fined as the start of sustained ROSC [16]. Shock on ad-
mission was defined as need for vasopressors,
intra-aortic balloon pump counterpulsation (IABP) or
other mechanical support to maintain a systolic BP > 80
mmHg for > 30 min after ROSC.
Randomisation, intervention and post cardiac arrest care
Randomisation was stratified by the centre in a 1:1 ratio be-
tween TTM at 33 °C (TTM-33) and 36 °C (TTM-36) and
temperature controlled using commercially available cool-
ing devices. Centres were encouraged to facilitate cooling
by using 30mL/kg of crystalloid fluid at cold or room
temperature, depending on temperature allocation. Target
temperature was induced and maintained for 28 h after
ROSC, followed by controlled rewarming at a maximum
rate of 0.5 °C/h. In the absence of pre-specified criteria,
withdrawal of life-supporting treatment was not allowed
prior to 108 h after randomisation [17]. Other management
decisions were at the discretion of the clinicians responsible
for the patient.
General data collection
The following data were collected from the TTM data-
base: demographics, pre-hospital factors, concurrent dis-
eases, status on arrival in hospital, Sequential Organ
Failure Assessment (SOFA) score, serum creatinine,
urine output, fluid balance, level of inotropic/vasoactive
support and use of renal replacement therapy (RRT) on
a daily basis until day 7 or discharge from ICU (which-
ever occurred first), ICU and hospital length of stay and
survival status at discharge and 6 months after CA.
Selection of patients for analysis of AKI after CA
To assess the development of AKI, patients surviving be-
yond day 2 after CA were included. Patients with
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end-stage renal failure on chronic dialysis before CA
were excluded. In the first analysis, the development of
AKI was stratified by temperature allocation. In a second
analysis, patients undergoing early coronary angiography
within 6 h of CA were compared with patients who had
delayed or no angiography. The 6-h time limit defining
early angiography in the study was chosen to allow time
for transport and primary resuscitation in case of
haemodynamic instability. If the time of angiography
was not available, patients were excluded from the angi-
ography analysis.
Renal function assessment
AKI was defined according to the KDIGO criteria [18]
with modifications. The analysis included the ICU length
of stay up to a maximum of 7 days. For the
creatinine-based criteria, we used the first recorded cre-
atinine after arrival in the hospital as the baseline value.
Daily serum creatinine was measured locally in hospital la-
boratories or using point-of-care devices. As only total
daily urine output data on individual days were recorded
in the case report forms, a mean hourly urine rate per day
was calculated and adjusted for the recorded body weight.
For this reason, we applied the urine criteria of the
KDIGO classification as follows: AKI stage 2 was defined
by a mean urine production < 0.5 mL/kg/h for the whole
24-h period, and AKI stage 3 was defined by a mean urine
production < 0.3mL/kg/h for the whole 24-h period. The
urine criterion was not used to define AKI stage 1. For a
summary of definitions, see Additional file 1: Table S1.
Patients were included in the study at any time of day.
As such, the 24-h urine output and fluid balance data
were incomplete on the day of CA (day 1) and also po-
tentially on the last day in ICU. To avoid misdiagnosing
patients as having AKI based on a potentially erroneous
low urine output, data from incomplete days were ex-
cluded from the analysis. The urine output on the last
day of ICU stay was disregarded if the patient stayed less
than 7 whole ICU days.
The worst stage of AKI based on serum creatinine,
urine output or initiation of RRT was determined on a
daily basis.
Statistical analysis
Data are presented as counts and percentages or, for con-
tinuous data, as mean (standard deviation) or median
[interquartile range (IQR)] depending on distribution.
Between-group comparisons were made using
chi-squared or Mann-Whitney U tests. Logistic regression
was used to assess the impact of TTM and early coronary
angiography on AKI. The model was adjusted for patient
factors and previous comorbidities [age, sex, hypertension,
diabetes, New York Heart Association (NYHA) heart fail-
ure class 3 or 4 and serum creatinine on admission],
cardiac arrest circumstances [applications of bystander
cardiopulmonary resuscitation (CPR), shockable rhythm,
time from CA to ROSC] and post cardiac arrest factors
(lactate clearance defined as a reduction of lactate > 50%
during the first 12 h or lactate < 2mmol/L at 12 h after
CA, use of vasopressors and/or inotropes, IABP insertion,
highest blood glucose during the first 24 h, temperature
allocation and angiography within 6 h of CA). As a sec-
ondary analysis, a logistic regression was performed to ad-
dress the impact of angiography within 36 h after the CA
on AKI. P < 0.05 was considered significant. No correc-
tions for multiple comparisons were made. The IBM SPSS
Statistics for Windows, Version 22 (IBM Corp. Armonk,
NY) was used for the required analyses.
Results
Nine hundred thirty-nine patients were included in the
original TTM study. Following the exclusion of 86 pa-
tients, 853 patients were included in the analyses (Add-
itional file 1: Figure S1). The patients excluded due to
early death survived 15 (IQR 10–21) hours after CA.
Seven hundred six patients (82%) were males, and the
median age was 65 (56–73) years. An initial shockable
rhythm was present in 80% with bystander CPR per-
formed in 625/853 patients (73%). The median time
from CA to ROSC was 25 (16–38) minutes. More than
80% of the patients required vasoactive drugs during the
first 3 days of intensive care and 112/859 (13%) were in
shock at the time of inclusion in the study. More than
half of the patients had a maximum circulatory SOFA
score of 4 during the first 3 days after CA (Table 1).
During days 2–7, 138 patients (16%) had maximum AKI
stage 1, 116 (14%) had AKI stage 2 and 127 (15%) had
AKI stage 3 of whom 74 received RRT. There were 472
patients (55%) who did not fulfil the AKI criteria. The
daily prevalence of AKI during the first week is shown in
Additional file 1: Figure S2. The number of patients diag-
nosed with AKI based on creatinine and urinary output
criteria is shown in Fig. 1. In 541 patients (264 TTM-33
and 277 TTM-36), their last day of the ICU stay was in-
complete because the patient left the ICU either due to
improvement or death/withdrawal of intensive care. Urine
output analysis was therefore excluded for that day.
Patients who developed AKI were characterised by an
older age, a greater proportion suffering from NYHA heart
failure stages 3 and 4, a lower incidence of a shockable
rhythm, a longer duration from CA to ROSC, a higher lac-
tate and serum creatinine on admission and more frequent
treatment with an IABP, while early angiography and
TTM-36 were associated with less AKI (Table 1).
Impact of TTM
In the unadjusted analysis, AKI was more common in pa-
tients randomised to TTM-33 compared to TTM-36 (49%
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versus 40%, p = 0.01). The severity of AKI was also worse
in the TTM-33 group (p = 0.018, Fig. 2), but there was no
difference in the proportion of patients who received RRT.
The TTM-33 group had a significantly more positive fluid
balance, and more patients required vasoactive drugs dur-
ing days 2–3 (Additional file 1: Table S2). Fifty-six percent
of patients in the TTM-33 group and 47% in the TTM-36
group had a cardiovascular SOFA score of 4 on at least
1 day during days 1–3 (p = 0.45).
Logistic regression analysis with correction for
co-morbidities and factors related to CA and critical care
demonstrated that TTM-36 was not an independent risk
factor for AKI (p = 0.10, odds ratio (OR) 0.75, 95% confi-
dence interval (CI) 0.54–1.06) (Table 2).
Impact of early coronary angiography
Early angiography within 6 h of CA was performed in 516/
836 patients (62%) (Table 3). The median time between CA
Table 1 Patient characteristics split into no AKI or any AKI
Baseline variables No AKI (n = 472) Any AKI (n = 381) p value
Age (years) 63 (54–72) 66 (59–74) 0.0001
Sex (male) 374 (79%) 321/381 (84%) 0.06
Body mass index 25.3 (23.3–27.8) 26.3 (24.2–29.7) < 0.0001
Hypertension 179/471 (38%) 162/379 (43%) 0.18
CHF (NYHA 3–4) 23/472 (5%) 33/379 (9%) 0.03
Any IHD, PCI, AMI, CABG 137/472 (29%) 129/377 (32%) 0.12
Diabetes 63/469 (13%) 58/379 (15%) 0.49
Cardiac arrest variables
Shockable rhythm 403/472 (85%) 283/381 (74%) < 0.0001
Bystander CPR 357/472 (76%) 268/381 (70%) 0.09
Time CA-ROSC (min) 23 (15–33) 29 (19–41) < 0.0001
Shock on admission 41/472 (9%) 71/381 (19%) 0.0001
Lactate on admission (mmol/L) 5.3 (2.7–8.4) (n = 437) 6.2 (3.0–9.8) (n = 362) 0.004
IABP 52/472 (11%) 84/381 (21%) < 0.0001
TTM 33 °C 220/472 (47%) 211/381 (55%) 0.01
Early angiography 301/459 (66%) 215/376 (57%) 0.01
Any vasoactive drug day 1 357/467 (76%) 292/378 (77%) 0.81
Day 2 384/466 (82%) 321/377 (85%) 0.30
Day 3 311/466 (67%) 301/377 (80%) < 0.0001
Noradrenaline or epinephrine > 0.1 μg/kg/min days 1–3 207/472 (44%) 233/381 (61%) < 0.0001
Renal variables/outcomes
Baseline creatinine (μmol/L) 100 (80–115) (n = 455) 110 (90–135) (n = 372) < 0.0001
Creatinine > 130 μmol/L 51/455 (11%) 99/372 (27%) < 0.0001
Worst AKI stage in the first week
Stage 1 NA 138/381 (36%) NA
Stage 2 NA 116/381 (30%) NA
Stage 3 NA 127/381 (33%) NA
Daily fluid balance
Day 2 1300 (400–2300) (n = 467) 1800 (800–3100) (n = 381) < 0.0001
Day 3 400 (− 700 to + 1100) (n = 454) 700 (− 100 to + 2000) (n = 376) < 0.0001
RRT during the first week NA 74/381 (20%) NA
Survival at 6 months 317/472 (67%) 159/381 (42%) < 0.0001
Patient characteristics, cardiac arrest-related factors, treatment and renal outcome data split into AKI or no AKI during days 2–7 of ICU stay
Abbreviations: CHF chronic heart failure, IHD ischaemic heart disease, PCI percutaneous coronary intervention, AMI acute myocardial infarction, CABG coronary
artery bypass grafting, CPR cardiopulmonary resuscitation, CA-ROSC time from cardiac arrest to return of spontaneous circulation, IABP intra-aortic balloon pump,
TTM target temperature management, RRT renal replacement therapy, NA not applicable
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and angiography was 2 (1–3) hours (Fig. 3). Two hundred
sixteen over five hundred seventeen (42%) of patients who
underwent early angiography developed AKI compared to
161/319 (50%) of patients who had an angiogram later than
6 h following OHCA or not at all (p = 0.014). The severity
of AKI was worse in patients without early angiography
(p = 0.007). This difference was driven by patients not re-
ceiving any angiography. Logistic regression analysis dem-
onstrated that increasing time to ROSC, a higher serum
creatinine on admission and treatment with IABP were in-
dependently associated with a higher risk of AKI whereas
an initial shockable rhythm was associated with less AKI.
Timing of angiography was not an independent risk factor
(p = 0.09) (Table 3). There were 128 patients in the late/no
angiography group who underwent angiography more than
6 h after the CA (range 7 h–68 days after CA, Add-
itional file 1, Fig. 3). A secondary analysis of angiography
prior to 36 h did not alter the results. Mortality
Since only patients surviving beyond day 2 were included
in the study, overall 6-month mortality was relatively low
at 44%. In patients with AKI stage 3, 6-month mortality
was significantly higher at 68% compared to 33% in pa-
tients without AKI (Fig. 4). Nine of 17 patients who were
still RRT-dependent 7 days after the CA were alive at 6
months with none of them requiring long-term dialysis.
Discussion
In survivors of OHCA from the presumed cardiac cause,
temperature management at 33 °C did not show different
rates of AKI from management at 36 °C. In addition,
emergency contrast angiography within 6 h of OHCA
was not associated with a higher risk of AKI compared
to later or no angiography. This finding is important and
should be evaluated in properly designed trials given the
possibility that the number of patients managed with
early angiography may increase if the recommended
clinical strategy for STEMI is extended to non-STEMI.
Fig. 1 The frequency of criteria used to determine the worst stage
of AKI days 2–7 after CA. AKI stages 2 and 3 are split into the
different diagnostic criteria urine output, S-creatinine concentration
or a combination thereof. For stage 1, AKI urine output criterion was
by study definition not applicable and as a consequence neither
was the combination of urine output and creatinine level
Fig. 2 The maximum stage of AKI during days 2–7 after cardiac
arrest stratified by temperature allocation. The category of AKI was
worse in the TTM-33 group (p = 0.018, Mann-Whitney U test)
Table 2 Results of logistic regression
Significance Odds
ratio
95% CI
Coronary angiography < 6 h 0.09 0.73 0.50–1.05
Temperature (36 °C) 0.10 0,75 0.54–1.06
Age (per year) 0.18 1.01 0.99–1.03
Sex (female) 0.09 0.67 0.43–1.06
Diabetes 0.07 0.61 0.36–1.04
Hypertension 0.60 1.10 0.77–1.58
Heart failure 0.50 1.26 0.64–2.46
Creatinine on admission 0.02 1.01 1.00–1.01
Time to ROSC (per minute) 0.05 1.01 1.00–1.02
Bystander CPR 0.62 1.10 0.74–1.63
Shock 0.18 1.42 0.84–2.41
Shockable rhythm 0.04 0.63 0.40–0.98
Lactate clearance 0.20 0.77 0.52–1.14
No vasopressor, dobutamine
or DA < 5 μg/kg/min
0.32
DA > 5 μg/kg/min or
NE < 0.25 μg/kg/min
0.52 0.87 0.56–1.34
NE or Epi≥ 0.25 μg/kg/min 0.30 1.34 0.77–2.35
NE or Epi≥ 0.75 μg/kg/min 0.67 1.23 0.43–3.47
IABP 0.003 2.22 1.32–3.74
Maximum blood glucose within 24 h 0.24 1.02 0.98–1.06
Results of logistic regression, angiography within 6 h of cardiac arrest vs. no
early angiography. Increasing time to ROSC, a higher serum creatinine on
admission and treatment with IABP were independently associated with a
higher risk of AKI whereas an initial shockable rhythm was associated with less
AKI. Normal lactate clearance was defined as lactate < 2.0 mmol/L alt 12 h or a
decrease in lactate > 50% within 12 h of cardiac arrest
Abbreviations: ROSC return of spontaneous circulation, CPR cardiopulmonary
resuscitation, DA dopamine, NE norepinephrine, Epi epinephrine, IABP
intra-aortic balloon pump
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Reported incidences of AKI after CA range from 12 to
81% depending on the definition used [1, 4]. Our finding
of an incidence of AKI of 45% is in line with previous
work [5, 19]. We also show an association between AKI
after OHCA and increased mortality, which again is in
agreement with previous reports [1, 2, 5, 19–21].
The TTM-33 group contained more patients with AKI
and more severe AKI than the TTM-36 group. The
temperature groups were reasonably well balanced with
regard to patient and cardiac arrest factors. We believe
the exclusion of patients who died on days 1 and 2 after
OHCA from our analysis did not affect our conclusions
Table 3 Patient characteristics split into angiography within 6 h of CA or later/no angiography
Coronary angiography
in the first 6 h (n = 516)
No coronary angiography
in first 6 h (n = 319)
p value
Baseline variables
Age (years) 63 (56–70) 69 (59–77) < 0.0001
Sex (male) 438/516 (85%) 247/319 (77%) 0.01
Hypertension 220/514 (43%) 118/319 (37%) 0.11
CHF (NYHA 3–4) 25/515 (5%) 31/319 (10%) 0.01
Any IHD, PCI, AMI, CABG 149/516 (29%) 118/319 (37%) 0.02
Diabetes 62/515 (12%) 59/316 (19%) 0.01
Cardiac arrest variables
Shockable rhythm 438/516 (84%) 231/319 (73%) < 0.0001
Bystander CPR 393/516 (76%) 223/319 (70%) 0.05
Time CA-ROSC (min) 25 (17–38) 25 (16–40) 0.85
Shock on admission 67/516 (13%) 44/319 (14%) 0.75
Lactate on admission (mmol/L) 5.1 (2.4–8.8) (n = 477) 6.2 (3.6–9.5) (n = 310) 0.001
ST-elevation on ECG 279/513 (54%) 57/315 (18%) < 0.0001
PCI 342/516 (66%) 23/319 (7%) < 0.0001
IABP 107/515 (20%) 25/319 (8%) < 0.0001
TTM 33 °C 254/516 (49%) 157/319 (49%) 1.00
Any vasoactive drug day 1 404/511 (79%) 233/317 (74%) 0.07
Day 2 438/510 (86%) 252/316 (80%) 0.03
Day 3 377/508 (74%) 221/317 (70%) 0.17
Noradrenaline or epinephrine > 0.1 μg/kg/min days 1–3 261/516 (50%) 171/317 (54%) 0.35
Renal variables/outcomes
Baseline creatinine (μmol/L) 100 (85–120) (n = 499) 105 (85–130) (n = 312) 0.04
Creatinine > 130 μmol/L 78/499 (16%) 68/312 (22%) 0.03
Worst AKI stage first week
Stage 1 86/516 (17%) 51/319 (16%) 0.85
Stage 2 59/516 (11%) 55/319 (17%) 0.02
Stage 3 71/516 (14%) 55/319 (17%) 0.20
Any AKI first week 216/516 (42%) 161/319 (50%) 0.02
Daily fluid balance
Day 2 1500 (500–2500) (n = 513) 1600 (500–2700) (n = 318) 0.64
Day 3 300 (− 500 to + 1400) (n = 504) 500 (− 400 to + 1800) (n = 309) 0.12
RRT during first week 47/516 (9%) 27/319 (9%) 0.80
Survival at 6 months 311/516 (60%) 153/319 (48%) 0.0006
Patient characteristics, cardiac arrest-related factors, treatment and renal outcome data split into patients exposed to angiography within the first 6 h of cardiac
arrest or not. Dichotomous results are presented as numbers and percentages; continuous data are presented as median and interquartile range. The p values
were calculated using Fisher’s exact test and Mann-Whitney test respectively
Abbreviations: CHF chronic heart failure, IHD ischaemic heart disease, PCI percutaneous coronary intervention, AMI acute myocardial infarction, CABG coronary
artery bypass grafting, CPR cardiopulmonary resuscitation, CA-ROSC time from cardiac arrest to return of spontaneous circulation, IABP intra-aortic balloon pump,
TTM target temperature management, RRT renal replacement therapy
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since death in the first 2 days was evenly distributed be-
tween temperature allocations. The patient characteristics
were also balanced with respect to the patient and cardiac
arrest factors. During the ICU stay, vasoactive drugs were
used more frequently in the TTM-33 group compared to
the TTM-36 group. This may reflect differences in cardio-
vascular performance between the groups. A previous
sub-study of the TTM trial including 171 patients showed
that patients randomised to TTM-33 had a reduced car-
diac index and increased systemic vascular resistance
compared to TTM-36 [22]. The optimal blood pressure/
perfusion parameters for renal recovery after cardiac ar-
rest are not known. In well-characterised patients with
vasoplegia, an increase in MAP from 60 to 75mmHg led
to an increase in glomerular filtration rate (GFR) and
Cr-EDTA clearance without further improvement with an
increase to 90mmHg [23, 24]. In OHCA patients, there is
an association not only between increasing MAP and im-
proved renal function indices, but also between increasing
level of vasoactive support and decreased GFR/increased
need for RRT [25]. Considering CA patients and renal
function, the optimal balance between MAP and vaso-
active support is not known. Patients in the TTM-33
group also received more intravenous fluids than the
TTM-36 group. Fluid overload is a risk factor for develop-
ment and progression of AKI [26, 27]. This aspect of clin-
ical management after CA deserves further attention in
future studies. After correction for important risk factors,
temperature allocation was no longer an independent risk
factor for AKI.
After correction for important risk factors, early angi-
ography was not independently associated with an in-
creased risk of AKI. This is encouraging, as fear of
contrast-induced nephrotoxicity may lead clinical teams
to withhold potentially life-saving emergency coronary
angiography unnecessarily. Similar results were noted by
Petek et al. [28]. Whether the TTM protocol recommen-
dation to administer intravenous fluids on induction of
TTM (30 ml/kg) modified the development of AKI is
unclear.
Our principal reason for focusing on the effects of
early angiography (within 6 h of CA) was to investigate a
clinical scenario in which the renal system is exposed to
several potentially harmful insults simultaneously. In the
post CA setting, where cardiac output may be reduced,
administration of contrast during emergency angiog-
raphy might potentially compromise the chances of
renal recovery further [29]. The lack of an increased in-
cidence of AKI in this setting is reassuring especially in
light of current guidelines [12] and consensus statements
[30, 31]. Early angiography may result in faster recovery
of cardiac function and better renal perfusion, which
may outweigh the potential risks associated with
contrast media. Our results are supported by a recent
study showing no significant difference in the release of
early AKI biomarkers in critically ill patients after
contrast exposure [32].
Both patient characteristics and OHCA factors were
associated with development of AKI. An increasing time
from CA to ROSC, an indicator of ischaemic burden,
was independently associated with a higher risk of AKI,
as was a higher serum creatinine on admission. The as-
sociation of the intensity of ischaemia/reperfusion injury
after CA (whether assessed as amount of epinephrine
administered, time to ROSC, lactate concentration or
the early presence of shock) and AKI has been noted in
several studies [3–5, 19, 21]. Increased serum creatinine
Fig. 3 The time from cardiac arrest to angiography. The majority of
patients had an early angiography (within 6 h of cardiac arrest). Note
varied time intervals
Fig. 4 The mortality in relation to the worst stage of AKI. The worst
AKI stage during the first 7 days of intensive care stay vs mortality at
6 months. The mortality was significantly higher in patients with
AKI (p < 0.001)
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concentrations on admission and risk of AKI are also
well described [4, 5, 19]. Thus, creatinine concentrations
have been incorporated in most AKI risk-scoring sys-
tems [33]. The reason for the increased baseline creatin-
ine concentration in our patient group developing AKI
is not known. Patient factors (age, pre-existing cardiac
failure, higher body mass index with associated muscle
mass and unrecognised CKD (chronic kidney disease)
and peri-arrest factors (longer time to ROSC and more
pronounced post ROSC haemodynamic instability) may
have contributed [34].
The presence of an IABP was strongly associated with the
development of AKI, but shock and poor lactate clearance
were not. Since the use of IABPs was unevenly distributed
between centres, availability and indications for its applica-
tion may have differed. It is possible that the use of IABP is a
surrogate marker of continued haemodynamic instability
and continued shock, but it is also possible that using an
IABP after OHCA increases the risk of AKI per se.
Early angiography was not independently associated
with a lower incidence of AKI. When extending the ana-
lysis to all patients with angiography during the ICU
stay, angiography was independently associated with a
reduction of AKI but the selection and survivor bias
contributes to this finding.
Limitations
It is important to acknowledge limitations to this post hoc
analysis based on a randomised controlled trial designed
primarily to address the postulated protective effect of
temperature control after OHCA, and therefore, the results
should be regarded as hypothesis generating. Data on
pre-existing renal function were not available. We elected
not to use the MDRD formula to assess baseline creatinine
since race (black/non-black) was unknown. The use of the
first recorded serum creatinine concentration on arrival to
the hospital might have underestimated baseline renal func-
tion resulting in a reduced incidence of AKI [1, 7]. How-
ever, we note that it takes 24–36 h for serum creatinine
changes to occur after a definite renal insult [35]. Therefore,
it is likely that the creatinine values within the immediate
period after OHCA are reasonably representative of
pre-existing values, but it is conceivable that we missed a
certain degree of unrecognised CKD. Since only daily urine
output data were available, the urinary criteria of the
KDIGO classification of AKI had to be modified, an ap-
proach commonly taken in large cohort studies [36]. The
consequence of this modification was likely to be a reduced
recorded incidence of AKI. Urine output may have been
modified by for instance initial volume loading,
cold-induced diuresis or use of diuretics; however, on day 2,
the first complete day included in the study, there was no
difference in urine output between TTM-33 and TTM-36.
Since the TTM-study was not randomised by timing of
angiography, there may be a selection bias towards early
angiography in relation to the first analysed rhythm (ven-
tricular fibrillation/tachycardia) and ECG findings (ST-ele-
vation) reflecting resuscitation guidelines. Haemodynamic
instability and cardiogenic shock may have played a less
prominent role in a similar selection bias because early
angiography was performed with similar frequency in
those patients excluded due to early death and those in-
cluded. Early angiography seems to have been employed
equally despite more pronounced lactate elevation and
cardiogenic shock in the excluded group.
We cannot exclude that the use of early angiography was
influenced by the initial creatinine concentration as the initial
creatinine was lower in the early angiography group. How-
ever, the patients excluded due to early death had higher
baseline creatinine than the included patients. Despite this,
early angiography was applied with similar frequency. The
necessary exclusion of 73 patients (8%) dying before the end
of day 2 after CA may have produced an unknown bias.
We cannot exclude that some patients in our study
may have been exposed to other early contrast examina-
tions, for instance to exclude a pulmonary embolism. Fi-
nally, the TTM trial data did not include the type or
volume of contrast administered including during coron-
ary angiography.
Conclusions
In survivors of OHCA from the presumed cardiac cause,
temperature management at 33 °C did not show different
rates of AKI from management at 36 °C. Coronary angi-
ography within 6 h of CA was not associated with an in-
creased incidence of acute kidney injury compared to
later or no coronary angiography. The additional effect
of coronary angiography on kidney function after cardiac
arrest was negligible compared to other factors causing
acute kidney injury after cardiac arrest.
The present results suggest that coronary angiography
should not be deferred in a patient after cardiac arrest
due to concerns over the risk of acute kidney injury.
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